GRI Bio Secures Financial Runway, Advances Novel Treatments for Fibrosis and Autoimmune Disease

LA JOLLA, CA – February 04, 2026

Clinical-stage biotechnology company GRI Bio, Inc. has bolstered its financial standing and reported significant progress in its mission to develop a new class of immune-modulating therapies. In a recent corporate update, the company detailed a successful capital raise that extends its operational runway into 2027, providing crucial funding to advance its lead candidate for idiopathic pulmonary fibrosis (IPF) following positive Phase 2a clinical data.

The announcement paints a picture of a company navigating the challenging biotech landscape by balancing promising scientific innovation with the stark realities of capital-intensive drug development. While the financial boost provides a much-needed lifeline, the company faces a volatile market and a competitive clinical environment as it pushes its novel platform forward.

A Financial Lifeline in a Turbulent Market

GRI Bio has successfully shored up its balance sheet, a critical maneuver in a sector where cash is king. The company reported raising approximately $14.5 million in gross proceeds through a combination of financing activities in December 2025 and January 2026. This included an $8.0 million public offering and a subsequent $6.5 million raised via its At The Market (ATM) offering. As of December 31, 2025, the company held $8.2 million in cash and cash equivalents.

This infusion is projected to fund operations into the first quarter of 2027. “Entering 2026 with a strong cash position, we are focused on advancing GRI-0621 in IPF, progressing GRI-0803 toward the clinic and executing our clinical strategy with capital discipline to drive long-term value creation,” stated Marc Hertz, PhD, Chief Executive Officer of GRI Bio, in the company's press release.

However, this financial runway comes amid a backdrop of significant cash burn. The company reported a net loss of $12 million for 2025, with research and development expenses nearly doubling to $6.8 million from $3.8 million in 2024, primarily driven by the costs associated with the GRI-0621 program. This burn rate places its projected runway of roughly 15 months on the tighter side of the 18-to-24-month cushion that industry analysts typically prefer for clinical-stage biotechs. The financial maneuvering also follows a period of extreme stock volatility, which saw the company’s share price decline by nearly 99% over the past year and led to a reverse stock split in January 2026 to maintain its Nasdaq listing.

A New Contender in the Fight Against Idiopathic Pulmonary Fibrosis

The strategic financing is intended to fuel the development of what GRI Bio hopes will be a transformative treatment for idiopathic pulmonary fibrosis, a relentless and fatal lung disease. The company announced positive topline data from its Phase 2a study of GRI-0621, an oral therapeutic designed to combat the disease.

IPF is characterized by progressive scarring of the lungs, leading to irreversible decline in respiratory function. Current standard-of-care treatments, such as pirfenidone and nintedanib, can slow the disease's progression but do not halt or reverse it and are often accompanied by difficult side effects. The unmet medical need remains exceptionally high.

GRI Bio’s approach with GRI-0621 is distinct. The drug is designed to inhibit the activity of Type I invariant Natural Killer T (iNKT) cells, a key driver of the inflammatory cascade that leads to fibrosis. The company reported that recent data not only confirmed the drug’s clinical proof-of-concept but also showed suppression of pro-fibrotic immune phenotypes and a direct impact on the core biology of lung repair. This unique mechanism could offer a significant advantage over existing therapies.

However, GRI-0621 is entering a competitive field. Other companies are also in the late-stage race to bring new IPF treatments to market. Boehringer Ingelheim's BI 1015550 and FibroGen's pamrevlumab are both in advanced development, highlighting the intense and costly competition to capture a share of this critical market.

Beyond Fibrosis: The Promise of a Broader NKT Platform

GRI Bio's strategy extends beyond a single disease. The positive results for GRI-0621 serve as a crucial validation for its underlying scientific platform, which focuses on modulating NKT cells to treat a range of inflammatory, fibrotic, and autoimmune diseases. The company is leveraging this platform to build a broader pipeline, underscored by its library of over 500 proprietary compounds.

The next asset in line is GRI-0803, which is being advanced into IND-enabling studies for autoimmune diseases. While the company's recent announcement was broad, preclinical data has pointed to Systemic Lupus Erythematosus (SLE) as a primary target. GRI-0803 is a novel agonist of type 2 NKT cells, a different subset than those targeted in IPF. In animal models of lupus, the compound demonstrated an ability to inhibit lupus nephritis—a severe kidney complication—and significantly improve survival.

Like IPF, SLE is a chronic condition with high unmet need. Current treatments often rely on broad immunosuppressants and come with a risk of serious side effects. By targeting a specific cellular pathway, GRI-0803 represents a more tailored approach that could offer a better safety and efficacy profile, positioning GRI Bio to potentially address a second major disease area with its NKT platform.

Wall Street's High-Stakes Bet on GRI Bio

The market's reaction to GRI Bio presents a study in contrasts. The company's stock performance reflects extreme investor caution, with the share price decimated over the past year. This performance reflects the inherent risks of clinical-stage drug development, shareholder dilution from capital raises, and the company's significant cash burn.

Yet, this bearish sentiment is juxtaposed with highly optimistic long-term targets from some Wall Street analysts. The average 12-month price forecast sits at $644.00, with some targets soaring as high as $1,008.00. This wide divergence suggests that while many investors are focused on the immediate financial risks, some analysts see the potential for a massive reward if GRI-0621 succeeds in its later-stage trials and the NKT platform proves its broad utility.

For now, GRI Bio has secured the resources to take its next critical steps. The company's future hinges on its ability to execute its clinical plans with the capital discipline it has promised, navigating a challenging financial market while advancing a novel scientific approach that could one day change the standard of care for patients with devastating diseases.